The liver is one of the organs in the human body we can’t live without. It's a complex organ that performs over 500 functions, including removal of harmful substances from the blood and absorbing nutrients. In the past, the only way to restore liver function was through a transplant. Now, those faced with liver disease have an alternative. Hepatologist Professor Rajiv Jalan (pictured) has invented a device that can remove the toxins from the bloodstream that accumulate due to liver failure. The DIALIVE device represents a huge breakthrough for patients suffering from organ failure due to liver disease. The first in-human trial of the DIALIVE device has been shown to be safe and effective. DIALIVE treatment led to a significant reduction in endotoxins, with patients who received as little as 3 days worth of treatments remaining in remission for 28 days afterwards. The next step will be a larger clinical trial, which, if successful, could see DIALIVE approved for clinical use within the next 2 years. It’s estimated that there are approximately 100 million people with liver disease that are at high risk of death. DIALIVE could be the lifeline that will change the outcome for many of those people.
Liver Dialysis Device Proved Safe and Effective For Treating Severe Liver Failure
The liver is one of the organs in the human body we can’t live without. It's a complex organ that performs over 500 functions, including removal of harmful substances from the blood and absorbing nutrients. In the past, the only way to restore liver function was through a transplant. Now, those faced with liver disease have an alternative. Hepatologist Professor Rajiv Jalan (pictured) has invented a device that can remove the toxins from the bloodstream that accumulate due to liver failure. The DIALIVE device represents a huge breakthrough for patients suffering from organ failure due to liver disease. The first in-human trial of the DIALIVE device has been shown to be safe and effective. DIALIVE treatment led to a significant reduction in endotoxins, with patients who received as little as 3 days worth of treatments remaining in remission for 28 days afterwards. The next step will be a larger clinical trial, which, if successful, could see DIALIVE approved for clinical use within the next 2 years. It’s estimated that there are approximately 100 million people with liver disease that are at high risk of death. DIALIVE could be the lifeline that will change the outcome for many of those people.